BRD4-TARGETED THERAPY ABBV-744 CLINICAL DATA NO FURTHER A MYSTERY

In Section A, individuals will receive different doses and schedules of oral ABBV-744 pill to discover Risk-free dosing regimen. Additional contributors might be enrolled in the discovered monotherapy dosign routine. In Segment B, members will receive oral ruxolitinib and ABBV-744 will be specified as "insert-on" therapy. In Phase C, members will r